Mayenga M, Assié JB, Monnet I, et al. - Approximately 2–3% of non-small–cell lung cancers (NSCLCs) harbor MET exon-14–skipping ( METex14) mutations, and immune-checkpoint inhibitors (ICIs) seem to be less effective among non-smokers and against tumors showing oncogenic addiction. Researchers here present six remarkable (progression-free survival more than 18 months) and durable responses to ICIs in patients suffering from NSCLCs harboring a METex14 mutation. They included 25 patients with METex14-mutated NSCLCs, of those, 13 were treated with ICIs and 6 demonstrated prolonged responses. Experts found no EGFR, BRAF or KRAS mutations (only 1 minority KRAS mutation), nor any ALK or ROS translocations. During the first 3 months, four partial and two complete responses were noted for five patients; pseudoprogression was initially seen in one. Excellent tolerance was reported. Response was sustained for 18–49 months. For patients suffering from NSCLCs harboring a METex14 mutation, ICIs should be considered. To detect patient groups with the highest likelihood of seeing a benefit from ICI treatment, there is a necessity for more biological marker data.